21 Aug 2023 , 10:11 AM
Lupin announced on Friday that it has purchased the trademark rights for the diabetes medications Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim for 26 million euros (Rs 235 crore) in an all-cash transaction.
Ondero and Ondero Met’s most recent sales were not disclosed by Lupin, however, the company did state that the acquisition was anticipated to add value to its range of diabetes medications.
As part of a co-marketing agreement with Boehringer Ingelheim India, Lupin has been promoting Ondero and Ondero Met in the Indian market since 2015.
As a global leader in the anti-diabetes market, Lupin further cemented its position with the acquisition of Ondero and Ondero Met, according to Nilesh Gupta, MD. ‘With the acquisition of Ondero and Ondero Met, we continue to offer a wide portfolio of products to enable access to medication for patients.’
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.